Brought to you by 
Hologic to pay $3.75bn in cash for Gen-Probe
02 Aug 2012
Executive Summary
In a move to become the largest diagnostics company focused on women’s health, Hologic Inc. is acquiring all the outstanding shares of fellow public company Gen-Probe Inc. (molecular diagnostics) for $82.75 each in cash (a 22% premium), valuing the transaction at $3.75bn.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Services
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hologic to pay $3.75bn in cash for Gen-Probe
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice